The anti-PD-L1 drug significantly extended survival in NSCLC patients with high PD-L1 expression compared to docetaxel, while alectinib shrank tumors for those with ALK-positive tumors and brain metastases.
The collaboration will leverage NanoString's nCounter Analysis System and PanCancer Immune Profiling technology in multiple prospective CITN clinical trials.
Researchers used NGS to profile the tumors of metastatic colorectal carcinoma patients enrolled in the CAPRI-GOIM clinical trial.
The panel evaluates both DNA and RNA, and is being used in the National Cancer Institute's Match trial.
The algorithm may be able to rationally determine the three-drug strategy with the best chance of overcoming resistance and improving survival in advanced lung cancer patients.
Clinical application of PD-L1 expression as a predictive marker won't be so straightforward because some patients with low expression also have a degree of response to Keytruda.
The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.
ARCA aims to boost participation by easing stringent enrollment criteria in a study investigating Gencaro in heart failure patients with a favorable response genotype.
The trial combines clinical NGS panels with research-based exome and transcriptome sequencing.
Merrimack will use RNAscope to select patients with heregulin-positive, locally advanced metastatic NSCLC for a Phase II clinical trial for the drug candidate MM-121.
The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.
60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.
In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.
GenomeWeb reports that Veritas Genetics is suspending its US operations.